

REPORT DOCUMENTATION PAGE					Form Approved OMB No. 0704-0188	
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.						
1. REPORT DATE (DD-MM-YYYY) 22/02/2018		2. REPORT TYPE Presentation		3. DATES COVERED (From - To) 02/22/2018-02/24/2018		
4. TITLE AND SUBTITLE Gastric Injury From Oral Iron Supplementation				5a. CONTRACT NUMBER		
				5b. GRANT NUMBER		
				5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Capt Gyorffy, Janelle				5d. PROJECT NUMBER		
				5e. TASK NUMBER		
				5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBASA-Lackland, TX 78236-9908 210-292-7141				8. PERFORMING ORGANIZATION REPORT NUMBER 17540		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBASA-Lackland, TX 78236-9908 210-292-7141				10. SPONSOR/MONITOR'S ACRONYM(S)		
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release. Distribution is unlimited.						
13. SUPPLEMENTARY NOTES Southern Regional Society of General Internal Medicine, New Orleans, LA Feb 22-24, 2017						
14. ABSTRACT Learning Objective 1: Recognize that iron pill gastritis is a known complication of oral supplementation but is not well recognized Learning Objective 2: Recognize that the toxic effect of iron on gastrointestinal mucosa is caused by focal erosive mucosal injury similar to a chemical burn and may be avoided through use of alternate forms such as liquid iron or IV iron supplementation. Case: A 32-year-old Caucasian male with a past medical history of Barrett's esophagus and esophagitis presented with abdominal pain, hematemesis, and hematochezia. Inpatient EGD showed severe esophagitis without active bleeding and multiple small erosions in the fundus without evidence of blood and relatively normal pylorus. The patient remained hemodynamically stable and his celebrex was discontinued. The patient was started on oral iron supplementation for iron deficiency anemia at hospital discharge.						
15. SUBJECT TERMS						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Clarice Longoria	
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (Include area code) 210-292-7141	

Title: Gastric Injury from Oral Iron Supplementation

Authors: Janelle Gyorffy MD¹, Guy Dooley DO², Darren Spearman MD²

1. Department of Internal Medicine, SAUSHEC, San Antonio, TX

2. Department of Gastroenterology, SAUSHEC, San Antonio, TX

ABSTRACT BODY:

Learning Objective 1: Recognize that iron pill gastritis is a known complication of oral supplementation but is not well recognized

Learning Objective 2: Recognize that the toxic effect of iron on gastrointestinal mucosa is caused by focal erosive mucosal injury similar to a chemical burn and may be avoided through use of alternate forms such as liquid iron or IV iron supplementation.

Case: A 32-year-old Caucasian male with a past medical history of Barrett's esophagus and esophagitis presented with abdominal pain, hematemesis, and hematochezia. Inpatient EGD showed severe esophagitis without active bleeding and multiple small erosions in the fundus without evidence of blood and relatively normal pylorus. The patient remained hemodynamically stable and his celebrex was discontinued. The patient was started on oral iron supplementation for iron deficiency anemia at hospital discharge.


One month later the patient had a follow up EGD that showed multiple new linear hyper-pigmented peripyloric extensions of unknown etiology. Tissue biopsy revealed pigmented foreign material that stained positive for iron. Patient's endoscopy findings were most consistent with pill gastritis from an oral iron supplement that had been initiated one month prior. Patient was transitioned to IV iron supplementation. Unfortunately, the patient was lost to follow up and repeat EGD to confirm resolution of those lesions was not obtained.

Discussion: Iron deficiency anemia is a very common condition with an estimated 25 percent prevalence worldwide (WHO). The typical treatment for iron deficiency anemia is through oral iron tablet supplementation. Iron pill gastritis is a known complication of oral supplementation but is not well recognized. However, there is evidence that mucosal injury associated with oral iron supplementation may actually be more widespread than previously realized. One case series found that 16% of patients taking oral iron tablets were discovered to have iron deposition on routine H&E staining. Of those with iron deposition, 63% had mucosal erosions and 80% had reactive gastritis. There was also a positive association between PPI use and iron deposition (Kaye et al). Iron deposition in the gastrointestinal tract is also found to be more common in conditions associated with iron overload states such as hemochromatosis, cirrhosis, or multiple blood transfusions (Haig et al).

The toxic effect of iron on gastrointestinal mucosa is thought to be caused by focal erosive mucosal injury similar to a chemical burn. The mechanism of injury is hypothesized to be mediated by oxygen free radical production causing tissue necrosis when the iron concentration overwhelms the normal energy-dependent absorption mechanisms (Murray et al). Furthermore, this is hypothesized to occur in a concentration dependent manner from oral tablets (Hashash et al).

Many patients taking oral iron tablets experience upper gastrointestinal symptoms such as nausea and dyspepsia which can result in non-compliance. Although it is commonly recognized that oral iron supplementation may lead to unpleasant side effects, the association between iron toxicity and mucosal injury is not as well documented. Use of alternate forms such as liquid iron or IV iron supplementation may be better tolerated as this route may have less local concentration effect on the gastrointestinal mucosa. Primary care providers should be aware of this common side effect and be familiar with other treatment modalities for iron deficiency anemia. They should also be aware that certain conditions like hemochromatosis and cirrhosis may predispose those patients to higher iron deposition in the gastrointestinal tract and increased risk of mucosal injury with oral iron supplementation.

Images:



A. Initial EGD of pylorus. B. Follow up EGD 1 month later showing multiple linear hyperpigmented peripyloric extensions. C. Gastric biopsy with iron stain demonstrating abundant blue staining iron in the pits, glands and lamina propria of the gastric biopsy. 200x.

Disclosure: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Air Force, the Department of the Army or the Department of Defense or the U.S. Government."